These observations suggested that 26S proteasome inhibitors could restore the impaired intracellular Zn homeostasis by the ZIP13 mutants; thus, the manipulation of 26S proteasome activity by inhibitory compounds might be a therapeutic approach for SCD-EDS caused by pathogenic mutant ZIP13 proteins. This evidence concerns the gene SLC39A13 and Ehlers-Danlos syndrome.